Public sector hospitals in India face a critical shortage of Desferal, a vital iron chelator, endangering thalassemia patients who cannot afford its high cost. India Today.

Desferal 500mg vials (NDC 0078-0467-91) will continue to be sold in 4-count cartons. For more information call (888) 463-6332 or visit FDA.gov. Related Content.

Novartis has assured that steps are being taken to ensure the adequate supply of Desferal, a drug crucial for treating iron overload in Thalassemia patients. The drug is manufactured exclusively ...

DESFERAL® (deferoxamine) is an injectable medicine indicated for the treatment of iron overload, which may occur for example following blood transfusions necessary for the treatment of beta ...

Thalassemia patients are struggling to access Desferal, with many government hospitals lacking the drug despite its critical role in managing iron overload from blood transfusions. NEW DELHI ...

MITEM PHARMA Acquires Worldwide Rights to DESFERAL® (deferoxamine) With the Backing of TECHLIFE CAPITAL and MACSF. September 25, 2024 02:13 AM Eastern Daylight Time.

Novartis, however, denied any current shortage. “Currently, there is no shortage of Desferal in Delhi or elsewhere in India,” a spokesperson told Business Today.

MASSY, France, September 25, 2024--MITEM PHARMA, the pharmaceutical laboratory based in France and dedicated to Medicines of Major Therapeutic Interest (M.I.T.M.), is pleased to announce the ...